Drug Discovery Services Market

Increasing R&D spending by pharmaceutical and biotechnology businesses will boost the market growth

Increasing need for innovative therapeutics across a range of therapeutic goals. Drug-finding services Rising need for innovative treatments for chronic illnesses and advancements in the  healthcare industry are predicted to be the main drivers of market expansion. Pharmaceutical and biopharmaceutical businesses still contract their research and development (R&D) operations to CROs, who offer R&D services and create engagement models to maximize R&D efficiency. Governments and pharmaceutical corporations are forced to look for answers and boost their investment in clinical trials due to the increased burden of chronic diseases.

As a result, there will be a greater need for drug discovery services.

Due to the rising incidence of these chronic conditions, there is a strong need for drugs, which opens up the new business potential for market of Drug Discovery Services. Thus, this aspect is anticipated to accelerate Drug Discovery Services' market revenue globally.

The Global Drug Discovery Services Market Industry experiences a notable increase in demand for biologics, driven by advancements in biotechnology and a growing understanding of complex diseases. Biologics, including monoclonal antibodies and vaccines, represent a significant portion of new drug approvals. In 2024, the market is projected to reach 25.0 USD Billion, reflecting the industry's shift towards biologics. This trend is expected to continue as more companies invest in biologics research and development, potentially leading to a market value of 106.7 USD Billion by 2035. The emphasis on biologics is likely to propel the Global Drug Discovery Services Market Industry forward, as companies seek innovative solutions to address unmet medical needs.

The Global Drug Discovery Services Market Industry is propelled by the increasing prevalence of chronic diseases, such as cancer, diabetes, and cardiovascular disorders. As these diseases continue to rise globally, there is an urgent need for effective therapeutic solutions, driving demand for drug discovery services. Pharmaceutical companies are focusing on developing targeted therapies and personalized medicine approaches to address these health challenges. The market's growth is expected to align with the rising incidence of chronic diseases, contributing to a projected market value of 106.7 USD Billion by 2035. This growing health burden underscores the importance of the Global Drug Discovery Services Market Industry in developing innovative treatments.

Regulatory agencies worldwide are increasingly supporting drug development processes, which positively impacts the Global Drug Discovery Services Market Industry. Initiatives aimed at expediting the approval of new drugs, such as the FDA's Breakthrough Therapy Designation, encourage innovation and reduce time to market for new therapies. This regulatory support fosters a conducive environment for drug discovery, enabling companies to bring novel treatments to patients more efficiently. As a result, the market is likely to experience substantial growth, with projections indicating a rise from 25.0 USD Billion in 2024 to 106.7 USD Billion by 2035. Such regulatory frameworks are essential for sustaining the momentum of the Global Drug Discovery Services Market Industry.

Technological innovations play a crucial role in shaping the Global Drug Discovery Services Market Industry. The integration of artificial intelligence, machine learning, and high-throughput screening technologies enhances the efficiency and accuracy of drug discovery processes. These advancements allow for faster identification of potential drug candidates, reducing time and costs associated with traditional methods. As a result, the market is poised for growth, with a projected compound annual growth rate of 14.12% from 2025 to 2035. The adoption of these technologies not only streamlines the drug discovery process but also improves the overall success rate of drug development, thereby driving the Global Drug Discovery Services Market Industry.

The Global Drug Discovery Services Market Industry is significantly influenced by the rising expenditure on research and development (R&D) by pharmaceutical and biotechnology companies. As organizations prioritize innovation to stay competitive, R&D budgets are expanding, facilitating the exploration of novel therapeutic targets and drug modalities. This trend is particularly evident in emerging markets, where increased investment in healthcare infrastructure supports drug discovery initiatives. The anticipated growth in R&D spending is expected to contribute to the market's expansion, with projections indicating a rise from 25.0 USD Billion in 2024 to 106.7 USD Billion by 2035. Such investments are likely to enhance the capabilities of the Global Drug Discovery Services Market Industry.

By Region, the study provides market insights into North America, Europe, Asia-Pacific and the Rest of the World. The North American Drug Discovery Services market, accounted for USD 8.79 billion in 2022 and is expected to exhibit a significant CAGR growth during the study period. Higher investments in drug discovery R&D, significant firms with established research infrastructure, and technical improvements can all be linked to the regional market's growth. As outsourcing is no longer only about cutting costs, a growing need for effectiveness, quality, and innovation is anticipated to support industry expansion.

Biologics are more expensive, so there is a large market for biosimilars in the United States. By 2023, it is anticipated that the U.S. market for drug development services will be one of the main competitors for biosimilars.

Further, the major countries studied in the market report are The U.S, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 2 DRUG DISCOVERY SERVICES MARKET SHARE BY REGION 2022 (%)

Source Secondary Research, Primary Research, MRFR Database and Analyst Review

The Asia Pacific drug discovery services market is predicted to grow at the greatest rate throughout the prediction period. Because of the availability of qualified people, cheaper prices, an effective regulatory environment, and high-quality data, the Region is quickly becoming a hub for outsourcing drug development activities. The second-largest pharmaceutical market in the world, Japan, is anticipated to provide CROs with a sizable potential, driving the industry. The updated Pharmaceutical Affairs Law in Japan encourages cancer and tissue diagnostics research, which is anticipated to accelerate market expansion in this area.

Moreover, the China market of Drug Discovery Services held the largest market share, and the India market of Drug Discovery Services was the fastest-growing market in the Asia-Pacific region.

The quick development of technology and the growth of metropolitan areas propels the European drug discovery services market. In addition, the European Medicines Agency (EMA) suggested that 39 new active medications and 97 new medicines be approved in 2020. The development of biologics and biosimilars has seen an increase in investment from biopharmaceutical firms, which is responsible for the rise in the number of authorized drugs in Europe.

The European market of Drug Discovery Services is anticipated to be driven by increasing expenditures made by many major companies in various clinical and non-clinical research activities that are outsourced to several CRO service providers and help with efficient product development. Further, the Germany market of Drug Discovery Services held the largest market share, and the U.K. market of Drug Discovery Services was the fastest-growing market in the European Region.

Leading market players are investing a lot of money in R&D to expand their product portfolios, which will spur further market growth for Drug Discovery Services. With significant industry changes, including new product releases, contractual agreements, mergers and acquisitions, increased investments, and collaboration with other organizations, market developments are also undertaking various strategic activities to expand their presence. To grow and remain in a market that is becoming increasingly competitive, Drug Discovery Services industry competitors must provide affordable products.

Manufacturing locally to cut operational costs is one of the main business tactics the Drug Discovery Services industry uses to serve customers and increase the market sector. The Drug Discovery Services industry has recently given medicine some of the most important advantages. The Drug Discovery Services market major player such as Advinus Therapeutics, Abbott Laboratories Inc., Albany Molecular Research Inc. (AMRI), Agilent Technologies Ubiquigent, Aurigene, AstraZeneca PLC, Charles River Laboratories International, and others are working on expanding the market demand by investing in research and development activities.

Charles River Laboratories International, Inc. specializes in a range of preclinical and clinical laboratory, gene therapy, and cell therapy services for the pharmaceutical, medical device, and biotechnology sectors. Charles River Labs purchased the bioanalytical services company Retrogenix (U.K.) in March 2021. With this purchase, Charles River's Scientific capabilities in off-target profiling for drug development and cell microarray technologies are strengthened.

The pharmaceutical, culinary, environmental, agriscience, and consumer products sectors and governments get testing and support services from the French laboratory organization Eurofins Scientific S.E., headquartered in Luxembourg. To expand their integrated drug discovery platform, DiscoveryOne, Eurofins, and Liverpool ChiroChem Ltd cooperated in September 2021 to provide additional chemical knowledge using LCC's fragment library and PROTAC linker molecules.